Navigation Links
CareFusion Reports Second Quarter Results
Date:2/9/2010

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical device company, today reported results from continuing operations for the three and six months ended Dec. 31, 2009.

"We continued to execute well during our second quarter and performed ahead of our expectations," said David Schlotterbeck, chairman and CEO of CareFusion. "Hospital capital spending made modest improvements during the quarter and we continued to win key customer contracts. We also benefited in our respiratory business from government and hospital flu preparedness planning.

"As I look ahead to the second half of the fiscal year, we will make progress on our long-term plans for growth, stepping up our investments in R&D and sales and marketing to grow our key franchises and extend into important market adjacencies."

CareFusion's reported results compare to the three and six month periods ended Dec. 31, 2008.

Revenue in the second quarter increased 5 percent to $1 billion, or 2 percent on a constant currency basis, driven primarily by increased sales in the company's Respiratory business and in its Medical Technologies and Services segment. Sequentially from the first quarter ended Sept. 30, 2009, revenue increased $96 million or 11 percent. Compared to a strong prior year period when the slowdown in hospital capital spending had not yet had an impact on the company's financial results, operating income declined to $127 million from $172 million. Income from continuing operations was $73 million, or $0.33 per diluted share.

Excluding nonrecurring items, adjusted operating income for the second quarter declined to $149 million from $177 million and adjusted net income decreased $22 million to $88 million, or $0.39 on an adjusted basis per diluted share.

Operating expenses, including selling, general and administrative (SG&A), research and development (R&D), and restructuring and acquisition integration charges in the second quarter totaled $351 million or 34 percent of total revenue. Excluding $22 million of nonrecurring items, adjusted operating expenses in the second quarter totaled $329 million, or 32 percent of total revenue. Adjusted SG&A expenses were $292 million, and R&D investments totaled $37 million.

Critical Care Technologies

Second quarter revenue for the Critical Care Technologies segment, which includes the company's Dispensing, Infusion and Respiratory businesses, increased 1 percent to $682 million, driven by a strong performance in the company's Respiratory business. On a constant currency basis, revenue decreased by 1 percent. Segment profit decreased to $111 million from $146 million. Adjusted segment profit decreased to $126 million from $148 million driven by the impact of the slowdown in hospital capital spending and higher allocated costs from standing up as a public company, which were only partially offset by strong results in the company's Respiratory business.

Medical Technologies and Services

Second quarter revenue for the Medical Technologies and Services segment, which includes the company's Infection Prevention and Medical Specialties businesses, increased 15 percent to $337 million, or 8 percent on a constant currency basis, driven by increased sales from the International Surgical Products and Interventional Specialties businesses. Segment profit decreased to $16 million from $26 million. Adjusted segment profit decreased to $23 million from $29 million, primarily driven by higher allocated costs from standing up as a public company.

Six-Month Results

For the first six months of fiscal 2010, revenue increased 3 percent to $1.9 billion. Operating income declined to $244 million from $262 million. Income from continuing operations was $128 million, or $0.58 per diluted share.

Excluding nonrecurring items, adjusted operating income for the first six months of fiscal 2010 decreased to $283 million from $297 million and adjusted net income increased $13 million to $174 million, or $0.79 on an adjusted basis per diluted share.

Operating expenses, including SG&A, R&D, and restructuring and acquisition integration charges in the first six months of fiscal 2010 totaled $685 million or 35 percent of total revenue. Excluding $39 million of nonrecurring items, adjusted operating expenses in the first six months of fiscal 2010 totaled $646 million, or 33 percent of total revenue. Adjusted SG&A expenses were $573 million, and R&D investments totaled $73 million.

Segment results for the six months ended Dec. 31, 2009 and 2008 are as follows:

    
    
    
    
    Critical Care Technologies     1H FY10          1H FY09       Y/Y
    --------------------------     -------          -------       ---
    Revenue                    $1,299 million    $1,293 million     0%
    -------                    --------------    --------------    ---
    Segment Profit               $212 million     $221 million     (4)%
    --------------               ------------     ------------     ---
    
    
    
    
    
    
    Medical Technologies &
     Services                   1H FY10        1H FY09      Y/Y
    ----------------------      -------        -------      ---
    Revenue                  $643 million   $591 million      9%
    -------                  ------------   ------------    ---
    Segment Profit            $32 million    $41 million    (22)%
    --------------            -----------    -----------   ----
    
    

Adjusted operating expenses, adjusted SG&A expenses, adjusted operating income, adjusted net income, adjusted diluted earnings per share and adjusted segment profit are non-GAAP financial measures and exclude restructuring and acquisition integration charges, nonrecurring spinoff related costs, nonrecurring tax items, and discontinued operations. Adjusted net income also excludes nonrecurring costs related to the bridge loan entered into in connection with the spinoff. A reconciliation of GAAP to non-GAAP financial measures is included later in this news release.

Additional Second Quarter and Recent Highlights

Additional second quarter and recent company highlights include:

  • Introducing under limited release new minimally invasive interventional products to treat spinal compression fractures. With planned general availability in April, CareFusion will offer a complete line of products for both kyphoplasty and vertebroplasty procedures;
  • Signing a 10-year, sole-source agreement to upgrade Tenet Healthcare's entire network of 50 member hospitals with the Alaris® system infusion pumps;
  • FDA lifting an injunction on manufacture and sale of the CareFusion Alaris® SE pump;
  • The New England Journal of Medicine publishing a study showing the superiority of CareFusion ChloraPrep® compared to povidone-iodine for surgical skin preparation;
  • Announcing six new Pyxis® medication management products at the 44th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition; and
  • Launching the CareFusion Knowledge Portal, a Web-based application providing hospitals with on-demand information to improve efficiency and medication safety, while reducing costs.

Fiscal 2010 Outlook

CareFusion increased its revenue guidance range to a range of $3.95 billion to $4.05 billion, up from the previous guidance range of $3.85 billion to $4.0 billion. In addition, the company narrowed its previously provided adjusted diluted EPS outlook for fiscal 2010 to a range of $1.40 to $1.45, the upper end of its previously provided guidance range of $1.35 to $1.45. The guidance for fiscal 2010 is based on an assumed diluted weighted average outstanding share count of approximately 223 million.

Conference Call

CareFusion will host a conference call today at 2 p.m. PST to discuss earnings results for the second quarter.

The number to call from within the United States is (888) 396-2384 or + 1 (617) 847-8711 Internationally, using the pass code 54684988. A replay of the conference call will be available from 5 p.m. PST on Feb. 9 through 8:59 p.m. PST on Feb. 16 and can be accessed by dialing (888) 286-8010 in the United States or +1 (617) 801-6888 Internationally and using the pass code 36977014.

The Conference Call will also be webcast live through the Investor Relations section, under Calendar of Events, on CareFusion's website at www.carefusion.com.

Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

About CareFusion Corporation

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, AVEA® and Pulmonetic Systems ventilation and respiratory products, ChloraPrep® products, MedMined™ services for infection surveillance, NeuroCare neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 15,000 people across its global operations. More information may be found at www.carefusion.com.

Use of Non-GAAP Financial Measures by CareFusion Corporation

This CareFusion news release presents the non-GAAP financial measures "adjusted operating expenses", "adjusted SG&A expenses", "adjusted operating income", "adjusted net income", "adjusted diluted earnings per share" and "adjusted segment profit". The most directly comparable measure for these non-GAAP financial measures are operating earnings, operating expenses, SG&A expenses, operating income, net income, diluted earnings per share and segment profit. The company has included below unaudited adjusted financial information for the quarters and six months ended December 31, 2009 and 2008, which present the company's results of operations after excluding restructuring and acquisition integration charges, nonrecurring spinoff related costs, nonrecurring tax items, and discontinued operations.

In addition, CareFusion presents the non-GAAP financial measure "adjusted diluted earnings per share" on a forward-looking basis. The most directly comparable forward-looking GAAP measure for the company is diluted earnings per share. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion's future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding CareFusion's financial condition and results of operations is included as Exhibit 99.3 to CareFusion's report on Form 8-K filed with the Securities and Exchange Commission on February 9, 2010.

Cautions concerning forward-looking statements

The CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; declining economic conditions could adversely affect our results of operations and financial condition; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under a consent decree with the FDA and our failure to comply with the requirements of the consent decree may have an adverse effect on our business; and we may face significant uncertainty in the industry due to government healthcare reform. The CareFusion news release and the information contained herein reflect management's views as of February 9, 2010. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    
    
                                 CAREFUSION CORPORATION
                     CONSOLIDATED AND COMBINED STATEMENTS OF INCOME
                                      (UNAUDITED)
    
                                     Quarter Ended         Six Months Ended
                                      December 31,            December 31,
    (in millions,                    -------------         -----------------
    except per share amounts)        2009      2008        2009       2008  
    ------------------------------------------------------------------------
    
    Revenue                         $1,019    $969       $1,942     $1,884
    Cost of Products Sold              541     495        1,013        973
                                       ---     ---        -----        ---
    Gross Margin                       478     474          929        911
    
    Selling, General and
     Administrative Expenses           305     256          602        536
    Research and Development
     Expenses                           37      41           73         78
    Restructuring and
     Acquisition Integration
     Charges                             9       5           10         35
                                       ---     ---          ---        ---
    Operating Income                   127     172          244        262
    
    Interest Expense and Other,
     Net                                24      23           66         55
                                       ---     ---          ---        ---
    Income Before Income Taxes         103     149          178        207
    Provision for Income Taxes          30      42           50         70
                                       ---     ---          ---        ---
    Income from Continuing
     Operations                         73     107          128        137
    Income (Loss) from
     Discontinued Operations,
     Net of Tax                         (3)     81           23        164
                                       ---     ---          ---        ---
    
    Net Income                         $70    $188         $151       $301
                                       ===    ====         ====       ====
    
    Per Share Amounts:(1)
    
    Basic Earnings (Loss) per
     Common Share:
      Continuing Operations          $0.33   $0.48        $0.58      $0.62
      Discontinued Operations       $(0.01)  $0.37        $0.11      $0.74
      Basic Earnings per Common
       Share                         $0.32   $0.85        $0.69      $1.36
    
    Diluted Earnings (Loss) per
     Common Share:
      Continuing Operations          $0.33   $0.48        $0.58      $0.62
      Discontinued Operations       $(0.01)  $0.37        $0.11      $0.74
      Diluted Earnings per Common
       Share                         $0.32   $0.85        $0.68      $1.36
    
    Weighted-Average Number of
     Common Shares Outstanding:
      Basic                          220.8   220.5        220.7      220.5
      Diluted                        222.2   220.5        221.7      220.5
    
    
    
    (1) Earnings per share calculations are performed separately for each
        component presented.  Therefore, the sum of the per share components
        from the table may not equal the per share amounts presented. 
    
    
    
                             CAREFUSION CORPORATION
                         ADJUSTED FINANCIAL INFORMATION
                                  (UNAUDITED)
    
                                             Quarter Ended December 31, 2009
                                             -------------------------------
                                                Discon-   
                                                tinued    Non-
    (in millions,                               Opera-   recurring  Adjusted
    except per common share amounts)     GAAP   tions(1)  Items(2)     (3)
    ------------------------------------------------------------------------
    Revenue                            $1,019     $-        $-       $1,019
    Cost of Products Sold                 541      -         -          541
                                          ---    ---       ---          ---
    Gross Margin                          478      -         -          478
    
    Selling, General and Administrative
     Expenses                             305      -       (13)         292
    Research and Development Expenses      37      -         -           37
    Restructuring and Acquisition
     Integration Charges                    9      -        (9)           -
                                          ---    ---       ---          ---
    Operating Income                      127      -        22          149
    
    Interest Expense and Other, Net        24      -         -           24
                                          ---    ---       ---          ---
    Income Before Income Taxes            103      -        22          125
    Provision for Income Taxes             30      -         7           37
                                          ---    ---       ---          ---
    Income from Continuing Operations      73      -        15           88
    Loss from Discontinued
     Operations, Net of Tax                (3)     3         -            -
                                          ---    ---       ---          ---
    
    Net Income                            $70     $3       $15          $88
                                          ===    ===       ===          ===
    
    Per Share Amounts:(4)
    Basic Earnings per Common Share     $0.32  $0.01     $0.07        $0.40
    Diluted Earnings per Common Share   $0.32  $0.01     $0.07        $0.39
    
    Weighted-Average Number of Common
     Shares Outstanding:
      Basic                             220.8  220.8     220.8        220.8
      Diluted                           222.2  222.2     222.2        222.2
    
    Effective Tax Rate                   29.4%   n/a      31.8%        30.2%
    
    (1) Reflects impact of the divestiture of the Company's audiology
        business.
    (2) Reflects nonrecurring charges related to the spinoff ($13 million),
        nonrecurring restructuring and acquisition integration charges and
        nonrecurring tax items.
    (3) Adjusted financial information reflects GAAP results adjusted on a
        non-GAAP basis to exclude nonrecurring items noted.
    (4) Earnings per share calculations are performed separately for each
        adjustment presented.  Therefore, the sum of the per share
        adjustments from the table above may not equal the adjusted per share
        totals presented.
    
    
    
                                 CAREFUSION CORPORATION
                            ADJUSTED FINANCIAL INFORMATION
                                      (UNAUDITED)
                    
                                           Six Months Ended December 31, 2009
                                           ----------------------------------
                                                 Discon-
                                                 tinued     Non-
    (in millions, except                         Opera-   recurring  Adjusted
    per common share amounts)            GAAP    tions(1)  Items(2)    (3)
    -------------------------------------------------------------------------
    Revenue                             $1,942      $-        $-     $1,942
    Cost of Products Sold                1,013       -         -      1,013
                                         -----     ---       ---      -----
    Gross Margin                           929       -         -        929
    
    Selling, General and
     Administrative Expenses               602       -       (29)       573
    Research and Development Expenses       73       -         -         73
    Restructuring and Acquisition
     Integration Charges                    10       -       (10)         -
                                           ---     ---       ---        ---
    Operating Income                       244       -        39        283
    
    Interest Expense and Other, Net         66       -       (22)        44
                                           ---     ---       ---        ---
    Income Before Income Taxes             178       -        61        239
    Provision for Income Taxes              50       -        15         65
                                           ---     ---       ---        ---
    Income from Continuing Operations      128       -        46        174
    Income from Discontinued
     Operations, Net of Tax                 23     (23)        -          -
                                           ---     ---       ---        ---
    
    Net Income                            $151    $(23)      $46       $174
                                          ====    ====       ===       ====
    
    Per Share Amounts:(4)
    Basic Earnings per Common Share      $0.69  $(0.11)    $0.21      $0.79
    Diluted Earnings per Common Share    $0.68  $(0.11)    $0.21      $0.79
    
    Weighted-Average Number of Common
     Shares Outstanding:
        Basic                            220.7   220.7     220.7      220.7
        Diluted                          221.7   221.7     221.7      221.7
    
    Effective Tax Rate                    28.3%    n/a      24.6%      27.2%
    
    (1) Reflects impact of (a) removing certain businesses that manufacture
        and sell surgical and exam gloves, surgical drapes and apparel and
        fluid management products in the U.S. market that were previously
        part of the Clinical and Medical Products segment of Cardinal Health
        and were retained by Cardinal Health upon the spinoff, and (b) the
        divestiture of the Company's audiology business.
    (2) Reflects nonrecurring charges related to the spinoff ($29 million),
        nonrecurring charges related to the bridge loan entered into in
        connection with the spinoff ($22 million), nonrecurring restructuring
        and acquisition integration charges and nonrecurring tax items.
    (3) Adjusted financial information reflects GAAP results adjusted on a
        non-GAAP basis to exclude nonrecurring items noted.
    (4) Earnings per share calculations are performed separately for each
        adjustment presented.  Therefore, the sum of the per share
        adjustments from the table above may not equal the adjusted per share
        totals presented.
    
    
    
    
                                 CAREFUSION CORPORATION
                             ADJUSTED FINANCIAL INFORMATION
                                      (UNAUDITED)
    
                                              Quarter Ended December 31, 2008
                                              -------------------------------
                                                   Discon-
                                                   tinued    Non-
    (in millions, except per                       Opera-  recurring  Adjusted
    common share amounts)                  GAAP    tions(1)  Items      (2)
    --------------------------------------------------------------------------
    Revenue                                 $969       $-      $-       $969
    Cost of Products Sold                    495        -       -        495
                                             ---      ---     ---        ---
    Gross Margin                             474        -       -        474
    
    Selling, General and Administrative
     Expenses                                256        -       -        256
    Research and Development Expenses         41        -       -         41
    Restructuring and Acquisition
     Integration Charges                       5        -      (5)         -
                                             ---      ---     ---        ---
    Operating Income                         172        -       5        177
    
    Interest Expense and Other, Net           23        -       -         23
                                             ---      ---     ---        ---
    Income Before Income Taxes               149        -       5        154
    Provision for Income Taxes                42        -       2         44
                                             ---      ---     ---        ---
    Income from Continuing Operations        107        -       3        110
    Income from Discontinued
     Operations, Net of Tax                   81      (81)      -          -
                                             ---      ---     ---        ---
    
    Net Income                              $188     $(81)     $3       $110
                                            ====     ====     ===       ====
    
    Per Share Amounts:(3)
    Basic Earnings per Common Share        $0.85   $(0.37)  $0.01      $0.50
    Diluted Earnings per Common Share      $0.85   $(0.37)  $0.01      $0.50
    
    Weighted-Average Number of Common
     Shares Outstanding: (4)
        Basic                              220.5    220.5   220.5      220.5
        Diluted                            220.5    220.5   220.5      220.5
    
    Effective Tax Rate                      28.2%     n/a    37.2%      28.6%
    
    (1) Reflects impact of (a) removing certain businesses that manufacture
        and sell surgical and exam gloves, surgical drapes and apparel and
        fluid management products in the U.S. market that were previously
        part of the Clinical and Medical Products segment of Cardinal Health
        and were retained by Cardinal Health upon the spinoff, and (b) the
        divestiture of the Company's audiology business.
    (2) Adjusted financial information reflects GAAP results adjusted on a
        non-GAAP basis to exclude nonrecurring items related to restructuring
        charges and acquisition integration charges and nonrecurring tax
        items.
    (3) Earnings per share calculations are performed separately for each
        adjustment presented.  Therefore, the sum of the per share
        adjustments from the table above may not equal the adjusted per share
        totals presented.
    (4) Reflects shares outstanding after the August 31, 2009 distribution of
        our common stock based on a ratio of 0.5 shares of our common stock
        for each common share of Cardinal Health.
    
    
                                   CAREFUSION CORPORATION
                               ADJUSTED FINANCIAL INFORMATION
                                         (UNAUDITED)
    
                                           Six Months Ended December 31, 2008
                                           ----------------------------------
                                                   Discon-
                                                   tinued    Non-
    (in millions, except per                       Opera-  recurring  Adjusted
    common share amounts)                  GAAP    tions(1)  Items      (2)
    --------------------------------------------------------------------------
    Revenue                                $1,884      $-       $-    $1,884
    Cost of Products Sold                     973       -        -       973
                                              ---     ---      ---       ---
    Gross Margin                              911       -        -       911
    
    Selling, General and
     Administrative Expenses                  536       -        -       536
    Research and Development Expenses          78       -        -        78
    Restructuring and Acquisition
     Integration Charges                       35       -      (35)        -
                                              ---     ---      ---       ---
    Operating Income                          262       -       35       297
    
    Interest Expense and Other, Net            55       -        -        55
                                              ---     ---      ---       ---
    Income Before Income Taxes                207       -       35       242
    Provision for Income Taxes                 70       -       11        81
                                              ---     ---      ---       ---
    Income from Continuing Operations         137       -       24       161
    Income from Discontinued
     Operations, Net of Tax                   164    (164)       -         -
                                              ---    ----      ---       ---
    
    Net Income                               $301   $(164)     $24      $161
                                             ====   =====      ===      ====
    
    Per Share Amounts: (3)
    Basic Earnings per Common Share         $1.36  $(0.74)   $0.11     $0.73
    Diluted Earnings per Common
     Share                                  $1.36  $(0.74)   $0.11     $0.73
    
    Weighted-Average Number of Common
     Shares Outstanding: (4)
        Basic                               220.5   220.5    220.5     220.5
        Diluted                             220.5   220.5    220.5     220.5
    
    Effective Tax Rate                       33.8%    n/a     31.4%     33.5%
    
    (1) Reflects impact of (a) removing certain businesses that manufacture
        and sell surgical and exam gloves, surgical drapes and apparel and
        fluid management products in the U.S. market that were previously part
        of the Clinical and Medical Products segment of Cardinal Health and
        were retained by Cardinal Health upon the spinoff, and (b) the
        divestiture of the Company's audiology business.
    (2) Adjusted financial information reflects GAAP results adjusted on a
        non-GAAP basis to exclude nonrecurring items related to restructuring
        charges and acquisition integration charges and nonrecurring tax
        items.
    (3) Earnings per share calculations are performed separately for each
        adjustment presented.  Therefore, the sum of the per share
        adjustments from the table above may not equal the adjusted per share
        totals presented.
    (4) Reflects shares outstanding after the August 31, 2009 distribution of
        our common stock based on a ratio of 0.5 shares of our common stock
        for each common share of Cardinal Health.

SOURCE CareFusion Corporation

RELATED LINKS
http://www.carefusion.com

'/>"/>

SOURCE CareFusion Corporation
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition
2. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
3. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
4. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
5. CareFusion Moves First Quarter Earnings Announcement to November 5
6. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
7. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
8. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
9. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
10. CareFusion Will Host an Earnings Conference Call on Feb. 9 to Discuss the Results for the Second Quarter of Fiscal 2010
11. FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
Breaking Medicine News(10 mins):